| __timestamp | BioCryst Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 19586000 |
| Thursday, January 1, 2015 | 72758000 | 29135000 |
| Friday, January 1, 2016 | 61008000 | 42791000 |
| Sunday, January 1, 2017 | 66962000 | 49577000 |
| Monday, January 1, 2018 | 84888000 | 89209000 |
| Tuesday, January 1, 2019 | 107068000 | 69099000 |
| Wednesday, January 1, 2020 | 122964000 | 75961000 |
| Friday, January 1, 2021 | 208808000 | 90467000 |
| Saturday, January 1, 2022 | 253297000 | 74552000 |
| Sunday, January 1, 2023 | 216566000 | 91593000 |
Unleashing insights
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioCryst Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, BioCryst's R&D expenses surged by over 300%, peaking in 2022 with a remarkable 253 million dollars. This aggressive investment reflects their focus on pioneering treatments in rare diseases. In contrast, Supernus Pharmaceuticals maintained a more steady growth, with R&D spending increasing by approximately 370% over the same period, reaching its highest in 2023. This consistent approach underscores their strategy of enhancing existing therapies. As these companies continue to innovate, their R&D spending patterns offer a glimpse into their future trajectories in the pharmaceutical landscape.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Zoetis Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Insmed Incorporated and Supernus Pharmaceuticals, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Supernus Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.